Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
7,357 total articles
Toast just crossed the profitability Rubicon. With $608M in free cash flow, $342M in net income on $6.2B revenue, and an institutional buyer stepping in, the stock offers a favorable asymmetric swing opportunity around $28.35. This trade pairs a clear entry and stop with a realistic upside target backed by improving fundamentals, resilient unit eco…
Alpha Metallurgical (AMR) offers a mid-term buying opportunity. The stock has corrected from its January highs, valuation multiples are reasonable on a P/B basis, and AMR's met coal focus positions it to benefit if import demand from India firm up. The trade is a guarded long with clearly defined entries, stop and target while acknowledging executi…
Wesdome offers exposure to high-grade underground gold production with a compact asset base and clear near-term catalysts (Kiena ramp, drilling results, potential M&A optionality). We set a tactical long trade with a defined entry, stop and target and a long-term horizon to capture operational derisking and re-rating.
Charter (CHTR) plunged into oversold territory after a sharp intra-day move, but the company's cash generation, low earnings multiple and clear operational catalysts make a controlled long the highest-probability trade. Entry at $184.94, stop at $174.00, target $258.11 — mid-term setup with room to extend on confirming data.
CAE is trading like it will re-accelerate into 2027, but legacy Defense contract issues, a lowered EPS growth target and stretched valuation argue otherwise. This note lays out a short trade: entry $25.25, stop $28.50, target $20.00, horizon 180 trading days. Catalyst calendar and risk checklist included.
TransDigm (TDG) has been punished on concerns around commercial exposure. The pullback creates an actionable long setup: the business prints industry-leading operating margins, generates roughly $1.88B in free cash flow and has an enterprise value of ~$93.4B - metrics that argue the current price understates resilience. We lay out an entry at $1,15…
Tesla's $25B-plus capex plan for 2026 spooked the market, but the company is investing in AI, robotics, chips and robotaxi hardware that can expand margins and create new high-margin services. Fundamentals show growth (16% sales growth in the quarter) and steady free cash flow ($6.22B reported) even with heavy investment plans. Technicals and senti…
Anterix owns one of the most strategically valuable spectrum positions for utilities and critical infrastructure. With a market cap near $840M, strong ROE, no debt and improving commercial traction, the stock looks mispriced versus the optional value embedded in 900 MHz. This trade idea lays out a concrete entry, stop and $75 target on a long-term …
Quest Diagnostics (DGX) looks like a reliable, cash-generative diagnostics platform with a modest valuation and technical momentum. A clear entry, stop and target give a sensible risk/reward for a position lasting up to 180 trading days while catalysts like dividend growth, increased buybacks and secular demand in esoteric testing support upside.
Intel's Q1 2026 results and updated guidance reframed the company as a core AI infrastructure play. Revenue of $13.58B and adjusted EPS of $0.29 surprised the market, data center sales grew 22%, and management says AI-related businesses now represent roughly 60% of revenue. The stock has ripped higher, so this is a structured long: enter at $82.75,…
RELX is a defensive business-information franchise that has seen its multiple reprice amid sector-wide AI fears. Recent customer wins, proof points of pricing power in legal services, and bullish technicals offer an actionable long setup. Entry $36.33, stop $33.00, target $44.00 for a mid-term (45 trading days) recovery trade.
Total Energy Services has run hard, but the operational cadence of well servicing, improving utilization and a conservative balance sheet still support a mid-term long. This trade idea gives a precise entry, stop and target with clear time horizons and risk framing for disciplined execution.
Legend Biotech (LEGN) is a commercially active CAR-T company whose CARVYKTI franchise is already generating meaningful revenue. At a $4.54B market cap the stock discounts a lot of upside from earlier-line indications, manufacturing expansion and healthy commercial metrics. Technicals show bullish momentum and short interest remains elevated, creati…
First American Financial offers a blend of defensive earnings from title and specialty insurance plus upside from a cyclical housing rebound. At roughly $70.53 with a P/E in the low-teens and $763M in free cash flow, the stock is set up for a tactical long into a recovering mortgage market. This trade outlines entry, stop and target with risk frami…
Credo (CRDO) just bought a silicon photonics specialist and management is forecasting more than $500M in optical revenue by fiscal 2027. With no debt, solid free cash flow and accelerating product cycles for AI data centers, the risk/reward for a mid-term long trade looks favorable despite lofty multiples. This trade idea lays out entry, stop, targ…
XPeng (XPEV) faces clear near-term growth pain — Q1 deliveries were down sharply year-over-year — but the company still offers diversified revenue levers (software/autonomy, robot/IRoN initiatives, and an OEM JV) that justify a tactical long entry. At a market cap of about $15.4B and a share price near $16.30, the risk/reward is favorable for a swi…
Abbott (ABT) trades near the low end of its 52-week range after recent guidance weakness and acquisition-related dilution fears. The business remains diversified across diagnostics, medical devices, nutrition and established pharmaceuticals, generating meaningful free cash flow and a 2.5% yield. This trade idea sets a clear entry at $92.41, a stop …
SoftBank Group (SFTBY) is trading at $18.76 with a market cap near $223.6B, a trailing P/E around 8.7 and a P/B of 1.76. The company is a diversified holding company whose value is increasingly tied to AI infrastructure (Arm, Vision Fund portfolio, Exol) and Japan telecom assets. With several near-term catalysts — PayPay IPO momentum, Exol rollouts…
Paccar's recent fundamentals and market positioning suggest a higher-than-consensus earnings outcome is likely. Free cash flow, parts resilience, and improving momentum argue for a tactical long over the next 45 trading days to capture a re-rating if results surprise. Entry at the current price, tight stop and two stepped targets balance risk/rewar…
Prenetics has built an early-stage subscription engine through IM8 that already surpassed $100M in annualized recurring revenue within its first year. The company sits on $171.1M of adjusted liquidity, no debt, and a lean float. If management converts a larger share of buyers to quarterly subscriptions and scales international distribution, revenue…
Century Therapeutics (IPSC) offers asymmetric upside for traders who want exposure to off-the-shelf iPSC-derived cell therapy programs. The stock trades around $2.25 with a market cap near $400M, negative free cash flow, but a string of clinical and preclinical catalysts over the next 6-12 months that could re-rate sentiment. This is a mid-term swi…
Kratos Defense (KTOS) sits at the intersection of two durable trends: rising defense budgets focused on affordable autonomous systems and the Pentagon's push for mass-produced unmanned platforms. The stock has corrected sharply from its $134 52-week high and now trades near $66.45. Fundamentals show 21.9% revenue growth and a $12.3B market cap, but…
Palantir moved from high-growth story to profitable AI platform in 2025-2026. The stock's recent pullback creates a tradeable entry that balances a bullish thesis (AI-driven commercial expansion and improving margins) against an obvious valuation overhang. This is a tactical, swing trade view: buy at $142.30, target $185 in the next 45 trading days…
Apple's next chapter is starting under new leadership at a moment when valuation premium, reliance on buybacks, and an uncertain product roadmap leave the stock vulnerable. We lay out a mid-term (45 trading days) short with entry at $273.44, a stop at $289.00 and a target of $245.00—an actionable trade that balances technical momentum against struc…
YGRAF is showing widening distribution: rising short interest, repeated high short-volume days and weakening momentum indicators despite a near-$1 handle. This trade idea lays out a mid-term (45 trading days) short with exact entry, stop and target, and a framework for what would invalidate the thesis.
